Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from MIRA Pharmaceuticals, Inc. ( (MIRA) ) is now available.
MIRA Pharmaceuticals announced positive results from a proof-of-concept study of its drug candidate Ketamir-2 in an animal model of PTSD, showing the drug restored normalized behavior in stressed animals. This supports further study designs and ongoing trials, potentially enhancing the company’s position in the treatment of PTSD and neuropathic pain.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of novel drug candidates. Its primary product, Ketamir-2, is an orally bioavailable new molecular entity targeting the NMDA receptor, designed to offer therapeutic benefits similar to ketamine but with reduced side effects.
Average Trading Volume: 1,354,012
Technical Sentiment Signal: Buy
See more insights into MIRA stock on TipRanks’ Stock Analysis page.